Literature DB >> 18403764

Challenges to HIV prevention--seeking effective measures in the absence of a vaccine.

Stephen W Lagakos1, Alicia R Gable.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18403764     DOI： 10.1056/NEJMp0802028

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  27 in total

Review 1.  Weighing the gold in the gold standard: challenges in HIV prevention research.

Authors:  Nancy S Padian; Sandra I McCoy; Jennifer E Balkus; Judith N Wasserheit
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

2.  Cross-sectional HIV incidence estimation in an evolving epidemic.

Authors:  Doug Morrison; Oliver Laeyendecker; Ron Brookmeyer
Journal:  Stat Med       Date:  2019-05-21       Impact factor: 2.373

Review 3.  Behavioral and biomedical combination strategies for HIV prevention.

Authors:  Linda-Gail Bekker; Chris Beyrer; Thomas C Quinn
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

4.  Achieving the potential of HIV prevention interventions: critical global need for collaborative dissemination efforts.

Authors:  Wynne E Norton; William A Fisher; Jeffrey D Fisher
Journal:  AIDS       Date:  2009-01-02       Impact factor: 4.177

5.  Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women.

Authors:  Stewart E Reid; James Y Dai; Jing Wang; Bupe N Sichalwe; Godspower Akpomiemie; Frances M Cowan; Sinead Delany-Moretlwe; Jared M Baeten; James P Hughes; Anna Wald; Connie Celum
Journal:  J Acquir Immune Defic Syndr       Date:  2010-04       Impact factor: 3.731

6.  Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada.

Authors:  Viviane D Lima; Robert S Hogg; Julio S G Montaner
Journal:  PLoS One       Date:  2010-06-07       Impact factor: 3.240

7.  Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: a comparison of the two control arms of HPTN 035.

Authors:  Barbra A Richardson; Cliff Kelly; Gita Ramjee; Thomas Fleming; Bonus Makanani; Sarah Roberts; Petina Musara; Nkhafwire Mkandawire; Thomas Moench; Anne Coletti; Lydia Soto-Torres; Salim A Karim
Journal:  J Acquir Immune Defic Syndr       Date:  2013-05-01       Impact factor: 3.731

Review 8.  Methodologies for evaluating HIV prevention intervention (populations and epidemiologic settings).

Authors:  Ronald H Gray
Journal:  Curr Opin HIV AIDS       Date:  2009-07       Impact factor: 4.283

9.  HIV-prevention science at a crossroads: advances in reducing sexual risk.

Authors:  Sten H Vermund; Katherine L Allen; Quarraisha Abdool Karim
Journal:  Curr Opin HIV AIDS       Date:  2009-07       Impact factor: 4.283

10.  Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A.

Authors:  Mainul Hoque; Hartmut M Hanauske-Abel; Paul Palumbo; Deepti Saxena; Darlene D'Alliessi Gandolfi; Myung Hee Park; Tsafi Pe'ery; Michael B Mathews
Journal:  Retrovirology       Date:  2009-10-13       Impact factor: 4.602
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.